These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9351290)

  • 1. New immunosuppressive agents for organ transplantation.
    Waer M
    Acta Clin Belg; 1997; 52(4):199-203. PubMed ID: 9351290
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunosuppressive agents: recent developments in molecular action and clinical application.
    Gerber DA; Bonham CA; Thomson AW
    Transplant Proc; 1998 Jun; 30(4):1573-9. PubMed ID: 9636637
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunosuppressive approaches to the prevention of graft vascular disease.
    Gregory CR
    Transplant Proc; 1998 May; 30(3):878-80. PubMed ID: 9595134
    [No Abstract]   [Full Text] [Related]  

  • 4. Review of immunosuppression for lung transplantation. Novel drugs, new uses for conventional immunosuppressants, and alternative strategies.
    Hausen B; Morris RE
    Clin Chest Med; 1997 Jun; 18(2):353-66. PubMed ID: 9187827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New small molecule immunosuppressants for transplantation: review of essential concepts.
    Morris RE
    J Heart Lung Transplant; 1993; 12(6 Pt 2):S275-86. PubMed ID: 7508752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive drugs.
    Collier SJ
    Curr Opin Immunol; 1989-1990; 2(6):854-8. PubMed ID: 2484794
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunosuppressive regimens of tomorrow.
    Groth CG
    Transplant Proc; 1995 Dec; 27(6):2971-3. PubMed ID: 8539797
    [No Abstract]   [Full Text] [Related]  

  • 8. New immunosuppressive drugs in transplantation.
    Groth CG; Ohlman S; Gannedahl G; Ericzon BG
    Transplant Proc; 1993 Aug; 25(4):2681-3. PubMed ID: 7689274
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunosuppressive effect of RS-61443 on rat cardiac allograft survival in combination with leflunomide or FK 506.
    D'Silva M; Antoniou E; DeRoover A; Nishimura Y; Howie A; McMaster P
    Transplant Proc; 1996 Apr; 28(2):930-1. PubMed ID: 8623467
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of splenectomy and mono- or combination therapy with rapamycin, the morpholinoethyl ester of mycophenolic acid and deoxyspergualin on cardiac xenograft survival.
    Wang J; Morris RE
    Transplant Proc; 1991 Feb; 23(1 Pt 1):699-702. PubMed ID: 1990655
    [No Abstract]   [Full Text] [Related]  

  • 11. New horizons in immunosuppression.
    Simmons RL; Wang SC
    Transplant Proc; 1991 Aug; 23(4):2152-6. PubMed ID: 1714645
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical and experimental immunosuppression.
    Castillo Lugo JA
    Bol Asoc Med P R; 1995; 87(5-6):106-8. PubMed ID: 8573248
    [No Abstract]   [Full Text] [Related]  

  • 13. FK 506 prevents islet xenograft rejection: a study in the pig-to-rat model.
    Song Z; Wennberg L; Bennet W; Sundberg B; Groth CG; Korsgren O
    Transplant Proc; 1999; 31(1-2):981. PubMed ID: 10083437
    [No Abstract]   [Full Text] [Related]  

  • 14. Triple drug treatment with cyclosporine, leflunomide and mycophenolate mofetil prevents rejection of pig islets transplanted into rats and primates.
    Wennberg L; Groth CG; Tibell A; Zhu S; Liu J; Rafael E; Söderlund J; Biberfeld P; Morris RE; Karlsson-Parra A; Korsgren O
    Transplant Proc; 1997 Aug; 29(5):2498. PubMed ID: 9270824
    [No Abstract]   [Full Text] [Related]  

  • 15. Tacrolimus enhances the immunosuppressive effect of cyclophosphamide but not that of leflunomide or mycophenolate mofetil in a model of discordant liver xenotransplantation.
    Miki T; Goller A; Rao A; Wang X; Yin WY; Tandin A; Fung JJ; Starzl TE; Valdivia LA
    Transplant Proc; 1998 Jun; 30(4):1091-2. PubMed ID: 9636444
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide.
    Brazelton TR; Morris RE
    Curr Opin Immunol; 1996 Oct; 8(5):710-20. PubMed ID: 8902398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New antirejection drugs anticipated.
    Randall T
    JAMA; 1990 Sep; 264(10):1225. PubMed ID: 1696999
    [No Abstract]   [Full Text] [Related]  

  • 18. Progressive change in tolerance mechanisms after withdrawing combination immunosuppression with cyclosporine and rapamycine or leflunomide.
    Lin Y; Waer M
    Transplant Proc; 1996 Dec; 28(6):3159. PubMed ID: 8962224
    [No Abstract]   [Full Text] [Related]  

  • 19. New immunosuppressive strategies in renal transplant recipients.
    Fischereder M; Kretzler M
    J Nephrol; 2004; 17(1):9-18. PubMed ID: 15151254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment effectively intercepts advanced acute cardiac rejection.
    Antoniou EA; Xu M; Howie A; Chondros K; McMaster P; D'Silva M
    Transplant Proc; 1997 Nov; 29(7):2888-91. PubMed ID: 9365604
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.